MG2512
/ Shanghai Mabgen Biopharmaceutical Technology
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
June 13, 2026
A Study of MG2512 Injection in Participants With Advanced Solid Tumors
(clinicaltrials.gov)
- P1 | N=116 | Recruiting | Sponsor: Shanghai Mabgen Biopharmaceutical Technology Co., Ltd. | Not yet recruiting ➔ Recruiting
Enrollment open • Oncology • Solid Tumor
1 to 1
Of
1
Go to page
1